Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II

Alzheimer Disease Clinical Trial

Official title:

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00089882
• Other study ID #: IA0057
• Secondary ID: 2R01HG002213-04B
• Status: Completed
• Phase: N/A
• First received: August 17, 2004
• Last updated: July 22, 2009
• Start date: May 2003
• Est. completion date: September 2006

Study information

• Verified date: July 2009
• Source: National Institute on Aging (NIA)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

The REVEAL II study provides healthy adult children and siblings of Alzheimer's disease patients with genetic testing and information about their own chances of developing the disease. The study will compare a condensed education and counseling program to the current more extensive program.

Description:

Alzheimer's disease (AD) is a common, progressive disease affecting memory and cognition. Apolipoprotein E (APOE) has been identified as a genetic factor that may increase the risk of developing Alzheimer's disease (AD). While several consensus statements have advised against the clinical use of APOE genotyping, each of these called for research to evaluate the impact of susceptibility genotyping and to explore the process of communicating about risk issues. The REVEAL I Study was funded in 1999 to enroll adult children of patients with AD to determine who would choose to obtain APOE genotyping, to devise an education and counseling protocol for the disclosure of APOE genotyping, and to study the impact of disclosing this information. The REVEAL I study demonstrated that Alzheimer's disease risk assessments with APOE genotyping can be given to relatives of people with Alzheimer's disease without causing severe adverse psychological or behavioral effects.

The REVEAL II study will examine whether receiving risk assessment and APOE genotyping disclosure through a Condensed Education and Counseling Protocol is as safe and as effective as receiving such information through our current Extended Protocol. This study will also examine whether there are any differences among groups who receive disclosure of APOE results and risk assessment by different provider types, such as a physician or a genetic counselor. At least one-third of the participants in REVEAL II will be African American, in order to explore how racial identity affects the desire to obtain genetic risk assessment and the impact of receiving it.

Individuals who have a parent or sibling affected by Alzheimer's disease may enter the study either by self-referral to the study coordinator or by recruitment. Participants will have a scheduled phone interview during which demographic information, their relative's medical history, attitudes toward genetic testing and risk assessment for Alzheimer's disease, and interest in going on to the next step of the study will be assessed. During the second step of the study, participants will be randomly assigned to one of three study arms. Participants in the control arm of the study will be given the full educational and counseling protocol as was originally developed in the first funding period of this study. All participants will have the opportunity to continue with the study and have their blood drawn for genotype analysis and risk assessment. Follow-up sessions will be provided with psychometric measures and questionnaires.

Participants will be seen by the genetic counselor for two follow-up appointments, six weeks and six months after disclosure of risk information. A final 12 month follow-up questionnaire will be completed by mail and will be followed by a phone call from the genetic counselor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 360
• Est. completion date: September 2006
• Est. primary completion date: September 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult children or siblings of people with Alzheimer's disease.

Exclusion Criteria:

• Adult children or siblings of people with Alzheimer's disease who are unable to visit a study site.

• Persons with currently untreated depression, anxiety or severe mood disturbances.

• Persons with cognitive deficits.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Procedure:
• APOE Genetic susceptibility testing

Locations

Country	Name	City	State
United States	Boston University School of Medicine, Alzheimer's Disease Center	Boston	Massachusetts
United States	Case Western Reserve University, Memory and Aging Center	Cleveland	Ohio
United States	Weill Medical College of Cornell University, Memory Disorders Program	New York	New York
United States	Howard University College of Medicine, National Human Genome Center	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
National Institute on Aging (NIA)	National Human Genome Research Institute (NHGRI)

Country where clinical trial is conducted

United States, 

References & Publications (5)

Hipps YG, Roberts JS, Farrer LA, Green RC. Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test. 2003 Spring;7(1):39-44. — View Citation

LaRusse S, Roberts JS, Marteau TM, Katzen H, Linnenbringer EL, Barber M, Whitehouse P, Quaid K, Brown T, Green RC, Relkin NR. Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genet — View Citation

Roberts JS, Barber M, Brown TM, Cupples LA, Farrer LA, LaRusse SA, Post SG, Quaid KA, Ravdin LD, Relkin NR, Sadovnick AD, Whitehouse PJ, Woodard JL, Green RC. Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med. 2004 Jul-Aug;6(4):197-203. — View Citation

Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC; REVEAL (Risk Evaluation and Education for Alzheimer's Disease) Study Group. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Al — View Citation

Roberts JS, LaRusse SA, Katzen H, Whitehouse PJ, Barber M, Post SG, Relkin N, Quaid K, Pietrzak RH, Cupples LA, Farrer LA, Brown T, Green RC. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):86-93. — View Citation

External Links

•   Alzheimer's Disease Genetics Fact Sheet (ADEAR Center)
•   Boston University Alzheimer's Disease Center - REVEAL study